COLLEGE PARK, Md., May 12 /PRNewswire/ -- BioSurface Engineering Technologies, Inc. (BioSET), of College Park, Maryland, announced today that a recent publication in the Journal of Vascular Surgery suggests HepaSil, a chemically modified heparin designed specifically for controlled drug release from medical devices, significantly improved the acute and subacute patency of small bore synthetic vascular grafts. Expanded polytetrafluoroethylene (ePTFE) remains the most commonly used synthetic graft material in peripheral vascular reconstructions when a patient’s own vasculature is not a suitable for transplant. Over 200,000 peripheral reconstructions are performed in the United States alone each year, with the vast majority of surgeries intended to treat serious limb ischemia and prevent possible loss of patients limb.
This study was conducted by Dr. Howard Greisler and his associates at the Loyola Medical Center, Maywood, Illinois and published in the May issue of the Journal of Vascular Surgery under the title “Silyl-heparin bonding improves the patency and in vivo thromboresistance of carbon-coated polytetrafluoroethylene vascular grafts.” Data from this study showed that in a pre-clinical animal model, the synthetic ePTFE grafts incorporated with HepaSil resulted in 100% of the grafts remaining patent 1 month after implant with a significant reduction in intraluminal thrombus when compared to controls.
Dr. Howard Greisler, principle investigator commented, “This was the second in our series of studies looking at using this modified heparin construct to improve early graft patency. We continue to build on our body of evidence suggesting the role this particular formulation may play. We plan further studies looking at even longer term patency endpoints to continue to evaluate the clinical benefit this compound may bring.”
Mr. Tom Roueche, President and CEO, commented, “Dr. Greisler and his team at Loyola are one of the world’s most respected research and surgical teams in the field of vascular surgery with numerous published studies on the use of vascular grafts. We are very fortunate indeed to have such a respected group report such positive results using our HepaSil compound and remain encouraged that this technology may lead to an improved alternative to the painful and costly procedure of harvesting a patients own vessels for vascular reconstructions.”
About BioSurface Technologies, Inc.
BioSurface Engineering Technologies, Inc., is an early stage private company dedicated to bringing therapeutic combinations to medical devices to improve performance and patient well being. BioSET’s HepaSil drug delivery mechanism and separately their synthetic peptides for tissue regeneration continue to show excellent results in pre-clinical studies for the treatment of vascular, orthopedic and chronic wound diseases. The company intends to capitalize on the growing trend toward drug/device combination products and seeks to offer their novel peptides and methods of delivery to industry partners. For more information, please visit BioSET’s website at: http://www.biosetinc.com/
CONTACT: Tom Roueche of BioSET, Inc., +1-301-405-8431 or troueche@biosetinc.com.
BioSET, Inc.
CONTACT: Tom Roueche of BioSET, Inc., +1-301-405-8431 ortroueche@biosetinc.com
Web site: http://www.biosetinc.com/
